Misha Rosenbach, MD
banner
misharosenbach.bsky.social
Misha Rosenbach, MD
@misharosenbach.bsky.social
Dermatologist (medical derm, granulomas [sarcoid & more], neutrophilic dzs [PG/Sweets/etc], inpatient derm, drug reactions [SJS/DRESS], MedEd, climate & sustainability) @pennmedicine.bsky.social Residency PD @PennDerm. Views mine, not medical advice
Reposted by Misha Rosenbach, MD
Chloe Villani at MGH on ICIs

The basics:

-113 FDA approved indications for ICIs with 12-65% response rate by tumor
-90% report iRAEs and rash is most common
-1-2% can get myocarditis with mortality about 50%
-iRAEs differ by ICI type

#ACR25
October 25, 2025 at 2:53 PM
Reposted by Misha Rosenbach, MD
A review of select immune checkpoints that have been identified

Immunology 101: T cells need 2 signals for full activation to migrate to the periphery

#ACR25
October 25, 2025 at 2:18 PM
Thank you for sharing this important work on neutrophilic diseases & #SweetSyndrome #Derm #DermSky #Dermatology

For more in a very brief mini 🧵 see below:

bsky.app/profile/mish...
I forgot to tag @jclinical-invest.bsky.social in the below #MedSky thread on Sweet Syndrome & our new pub exploring keratinocyte-neutrophil interactions leading to persistent skin neutrophils in Sweets

(Pics from dermnet.nz):
#DermSky
October 20, 2025 at 5:39 PM
Thank you for tagging and for highlighting this important work! See here for a little more / mini 🧵:

bsky.app/profile/mish...
I forgot to tag @jclinical-invest.bsky.social in the below #MedSky thread on Sweet Syndrome & our new pub exploring keratinocyte-neutrophil interactions leading to persistent skin neutrophils in Sweets

(Pics from dermnet.nz):
#DermSky
October 20, 2025 at 5:37 PM